spacer
home > > autumn 2009 > reduction, replacement, refinement
PUBLICATIONS


Reduction, Replacement, Refinement

Fifty years ago, two British scientists, William Russell and Rex Burch, published a book entitled The Principles of Humane Experimental Research (1). This book paved the way for an ethos now shared by many scientists, namely that there is a fundamental obligation on those who conduct experiments on sentient species to ensure that harm is kept to an absolute minimum. Here we look at how animal testing can be reduced in the context of the current research and testing climate.

DRIVING FORCES THAT INFLUENCE ANIMAL TESTING

Many factors influence trends in the use of animals in research, testing and training, including the societal, economic, and political and market climates. For instance, concerns over the safety of chemicals that, in some cases, have been in common use for many decades, has culminated in the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) legislation that threatens to demand the conduct of around four million animal tests for existing chemicals. The mere existence of the REACH legislation is a reflection of the increasing threat of litigation that has stemmed from improved public and scientific awareness of the potential harm caused by everyday exposure to chemicals. By the same token, societal pressure is a major factor in determining the provisions of the Cosmetics Directive 76/768/EEC that, by 2013, will prohibit testing of cosmetic and toiletry ingredients and that has already banned the EU marketing of products tested on animals. The provisions of the Cosmetics Directive have spurred the cosmetics industry to develop non-animal methods to replace animal tests. Similarly, the REACH legislation, with its tight implementation timelines and disconcerting animal welfare and financial burden, has encouraged stakeholders to examine how existing non-animal alternatives and information can be used to best effect.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Nirmala Bhogal graduated with a BSc (Hons) in Biochemistry and Pharmacology, a PhD in Biochemistry and Molecular Biology and a postgraduate degree in Law. Her expertise is in the preclinical development of small chemical drugs and protein hormone mimetics. Nirmala joined FRAME in 2004 and currently oversees the FRAME Research Programme, working closely with scientists within the FRAME Alternatives Laboratory based at the University of Nottingham. Her area of research focuses on the evaluation of medicinal products.

Rita Seabra graduated with a BSc in Biology from the University of Glamorgan, South Wales and undertook her PhD in the School of Pharmacy at the University of Nottingham. Her research career included work on wound healing. Her interests at FRAME include systems biology, immune modulation and genetically-altered animals.

Michelle Hudson graduated from the University of Sheffield with a Master degree in Zoology. Her main research interests are the application of methods to reduce the number of animals used in experiments, the refinement and regulation of animal procedures and the replacement of laboratory non-human primates.

spacer
Nirmala Bhogal
spacer
spacer
spacer
Rita Seabra
spacer
spacer
spacer
Michelle Hudson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

BEERSE, BELGIUM, May 18, 2020 The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.[i] Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.[ii],[iii] Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), duration of response, as well as the safety profile of amivantamab,1 which were the basis of the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation granted earlier this year.[iv]
More info >>

White Papers

Digital Transformation of the Cold Chain

Sensitech EMEA

The Life Sciences cold chain is a seamless and interconnected global network of people, equipment, data and processes that helps to ensure the safety and integrity of our medicines and vaccines. Cold chain logistics spending totaled $13 billion in 2017, an investment designed to protect some $283 billion in Life Sciences cold chain products, growing at 19% annually.1 Sensitech Inc., a part of UTC Climate, Controls & Security, a unit of United Technology Corp., has played an essential part in the Life Sciences cold chain since 1990, providing a comprehensive set of solutions for manufacturers of biologics, prescription pharmaceuticals, clinical trial materials, and over-the-counter drugs. These solutions help to ensure product quality, patient safety, and regulatory compliance while helping to prevent theft and optimizing cold chain performance.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement